Vardenafil and methylarginines in pulmonary hypertension

Vardenafil and methylarginines in pulmonary hypertension

Background: Pulmonary hypertension (PH) is a rare condition characterized by endothelial dysfunction and vascular remodelling, leading to increased pulmonary vascular resistance (PVR) and right ventricular heart failure. Endothelial dysfunction is associated with an imbalance between vasoconstrictor...

Full description

Bibliographic Details
Main Author:	Sandqvist, Anna
Format:	Doctoral Thesis
Language:	English
Published:	Umeå universitet, Klinisk farmakologi 2016
Subjects:	vardenafil pulmonary hypertension pharmacokinetics haemodynamics right heart catheterization adenosine dimethylarginines phosphodiesterase type 5 inhibitors endothelin receptor antagonists
Online Access:	http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-113903 http://nbn-resolving.de/urn:isbn:978-91-7601-376-2

Similar Items

Rapidly progressive idiopathic pulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-03-01)

Favorable Evolution of a Patient with Thromboembolic Pulmonary Hypertension
by: Nedelcu Cristina, et al.
Published: (2017-05-01)

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study
by: Yosuke Tanaka, et al.
Published: (2017-12-01)

The use of combination therapy in pulmonary arterial hypertension: new developments
by: N. Galiè, et al.
Published: (2009-09-01)

Therapeutic strategies in pulmonary hypertension
by: Leonello eFuso, et al.
Published: (2011-04-01)

New perspectives in pulmonary arterial hypertension treatment: 2009 European recommendations
by: T. V. Martynyuk, et al.
Published: (2010-04-01)

Portopulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-11-01)

REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome
by: Ridwan Shabsigh, MD, FACS, et al.
Published: (2016-09-01)

Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction
by: Safar Israilovich Gamidov, et al.
Published: (2009-10-01)

Vardenafil increases intracellular accumulation of the most prevalent mutant cystic fibrosis transmembrane conductance regulator (CTFR) in human bronchial epithelial cells
by: Barbara Dhooghe, et al.
Published: (2020-08-01)

Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01)

Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
by: S N Avdeev
Published: (2015-09-01)

Clinical study about different doses of vardenafil for the treatment of neonatal persistent pulmonary hypertension
by: Qing-Jun Yi, et al.
Published: (2018-04-01)

Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
by: N A Tsareva
Published: (2013-12-01)

First clinical experience with endothelin receptor antagonist bosentan used in patients with pulmonary hypertension: results of a one-year study
by: S N Avdeev, et al.
Published: (2013-03-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
by: Monaco TJ, et al.
Published: (2016-05-01)

2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION
by: Nazzareno Galiè, et al.
Published: (2016-05-01)

The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension
by: S N Avdeev
Published: (2016-07-01)

Impact of advanced medical therapy for the outcome of an adult patient with Eisenmenger syndrome
by: Eglė Ereminienė, et al.
Published: (2017-01-01)

Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease
by: L.S. Howard
Published: (2011-12-01)

A clinical case of long-term macitentan therapy in a female patient with idiopathic pulmonary hypertension
by: O A Arkhipova, et al.
Published: (2016-12-01)

Lower doses of bosentan in combination with sildenafil might be beneficial in pulmonary arterial hypertension
by: Ahmad Amin, et al.
Published: (2015-01-01)

Legochnaya arterial'naya gipertenziya: na puti ot ratsional'noy diagnostiki k vyboru effektivnoy lekarstvennoy terapii
by: I E Chazova, et al.
Published: (2013-06-01)

Looking to the future: a new decade of pulmonary arterial hypertension therapy
by: V.V. McLaughlin
Published: (2011-12-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: O A Arkhipova, et al.
Published: (2018-06-01)

Endothelin receptor antagonist bosentan role in modern strategy for patients with pulmonary arterial hypertension treatment
by: Arkhipova O.A., et al.
Published: (2018-05-01)

Pulmonary hypertension: A simplified pulmonologists' perspective
by: Ketaki Utpat, et al.
Published: (2021-01-01)

Comparison Between the Acute Pulmonary Vascular Effects of Oxygen with Nitric Oxide and Sildenafil
by: Ronald W. Day
Published: (2015-03-01)

Pulmonary hypertension: reasonable selection of specific therapy
by: N A Karoli, et al.
Published: (2018-03-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

Right heart catheterization datas may not reflect the pulmonary hypertension epidemiology accurately
by: Yusuf Ziya Şener, et al.
Published: (2019-03-01)

Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
by: M. Delcroix, et al.
Published: (2009-12-01)

The effects of vardenafil and pentoxifylline administration in an animal model of ischemic colitis
by: Mehmet Aziret, et al.
Published: (2014-11-01)

Pharmacological Potential of Endothelin Receptors Agonists and Antagonists
by: Jiří Patočka, et al.
Published: (2005-01-01)

Effectiveness of sildenafil in pulmonary hypertension secondary to mitral valve disease
by: Tinni Mitra, et al.
Published: (2020-01-01)

The impact of the new World Symposium on Pulmonary Hypertension definition of pulmonary hypertension on the prevalence of pre-capillary pulmonary hypertension
by: Ümit Yaşar Sinan, et al.
Published: (2019-10-01)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
by: Correale M, et al.
Published: (2018-10-01)

Pharmacological test with sildenafil at pulmonary hypertension assessing in children with congenital heart diseases
by: O. S. Yanulevich, et al.
Published: (2010-10-01)

Clinical deterioration after sildenafil cessation in patients with pulmonary hypertension
by: Anne M Keogh, et al.
Published: (2008-10-01)